Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Pharmacokinetic and Pharmacodynamic Effects of Oral CXA-10, a Nitro Fatty Acid, After Single and Multiple Ascending Doses in Healthy and Obese Subjects.

Garner RM, Mould DR, Chieffo C, Jorkasky DK.

Clin Transl Sci. 2019 Jul 25. doi: 10.1111/cts.12672. [Epub ahead of print]

PMID:
31343124
2.

CXA-10, a Nitrated Fatty Acid, Is Renoprotective in Deoxycorticosterone Acetate-Salt Nephropathy.

Arbeeny CM, Ling H, Smith MM, O'Brien S, Wawersik S, Ledbetter SR, McAlexander A, Schopfer FJ, Willette RN, Jorkasky DK.

J Pharmacol Exp Ther. 2019 Jun;369(3):503-510. doi: 10.1124/jpet.118.254755. Epub 2019 Mar 20.

PMID:
30894457
3.

Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases.

Schopfer FJ, Vitturi DA, Jorkasky DK, Freeman BA.

Nitric Oxide. 2018 Sep 1;79:31-37. doi: 10.1016/j.niox.2018.06.006. Epub 2018 Jun 23. Review.

4.

Evaluation of 10-Nitro Oleic Acid Bio-Elimination in Rats and Humans.

Salvatore SR, Vitturi DA, Fazzari M, Jorkasky DK, Schopfer FJ.

Sci Rep. 2017 Jan 5;7:39900. doi: 10.1038/srep39900.

5.

Nitro-fatty acid pharmacokinetics in the adipose tissue compartment.

Fazzari M, Khoo NK, Woodcock SR, Jorkasky DK, Li L, Schopfer FJ, Freeman BA.

J Lipid Res. 2017 Feb;58(2):375-385. doi: 10.1194/jlr.M072058. Epub 2016 Dec 2.

6.

Man versus machine: is there an optimal method for QT measurements in thorough QT studies?

Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK.

J Clin Pharmacol. 2006 Jun;46(6):598-612.

PMID:
16707406
7.

Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects.

Prabhakar U, Conway TM, Murdock P, Mooney JL, Clark S, Hedge P, Bond BC, Jazwinska EC, Barnes MR, Tobin F, Damian-Iordachi V, Greller L, Hurle M, Stubbs AP, Li Z, Valoret EI, Erickson-Miller C, Cass L, Levitt B, Davis HM, Jorkasky DK, Williams WV.

DNA Cell Biol. 2005 Jul;24(7):410-31.

PMID:
16008510
8.

The effect of acarbose on the pharmacokinetics of rosiglitazone.

Miller AK, Inglis AM, Culkin KT, Jorkasky DK, Freed MI.

Eur J Clin Pharmacol. 2001 May;57(2):105-9.

PMID:
11417440
9.

Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.

Inglis AM, Miller AK, Culkin KT, Finnerty D, Patterson SD, Jorkasky DK, Freed MI.

J Clin Pharmacol. 2001 Jun;41(6):683-90.

PMID:
11402638
10.

Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.

Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK.

Thromb Haemost. 2001 Mar;85(3):435-40. Erratum in: Thromb Haemost 2001 Aug;86(2):727.

PMID:
11307810
11.

Rosiglitazone does not alter the pharmacokinetics of metformin.

Di Cicco RA, Allen A, Carr A, Fowles S, Jorkasky DK, Freed MI.

J Clin Pharmacol. 2000 Nov;40(11):1280-5.

PMID:
11075314
12.

Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.

Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK, Freed MI.

J Clin Pharmacol. 1999 Nov;39(11):1189-94.

PMID:
10579151
13.

The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline.

Nix DE, Di Cicco RA, Miller AK, Boyle DA, Boike SC, Zariffa N, Jorkasky DK, Schentag JJ.

J Clin Pharmacol. 1999 Aug;39(8):855-65.

PMID:
10434239
14.

Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone.

Freed MI, Wilson DE, Thompson KA, Harris RZ, Ilson BE, Jorkasky DK.

Clin Pharmacol Ther. 1999 May;65(5):473-82.

PMID:
10340912
15.

Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.

Kovacs SJ, Tenero DM, Martin DE, Ilson BE, Jorkasky DK.

Pharmacotherapy. 1999 May;19(5):612-9.

PMID:
10331824
16.

Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.

Tran JQ, Di Cicco RA, Sheth SB, Tucci M, Peng L, Jorkasky DK, Hursting MJ, Benincosa LJ.

J Clin Pharmacol. 1999 May;39(5):513-9.

PMID:
10234600
17.

Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.

Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, Loh R, Simoes EA, Sly P, Miller AK, Nichols AI, Jorkasky DK, Everitt DE, Thompson KA.

Antimicrob Agents Chemother. 1999 May;43(5):1183-8.

18.

Systemic exposure to rosiglitazone is unaltered by food.

Freed MI, Allen A, Jorkasky DK, DiCicco RA.

Eur J Clin Pharmacol. 1999 Mar;55(1):53-6.

PMID:
10206085
19.

What does the clinician want to know from the toxicologist?

Jorkasky DK.

Toxicol Lett. 1998 Dec 28;102-103:539-43.

PMID:
10022309
20.

Effect of age and gender on the pharmacokinetics of eprosartan.

Tenero DM, Martin DE, Miller AK, Ilson B, Boike SC, Zariffa N, Jorkasky DK.

Br J Clin Pharmacol. 1998 Sep;46(3):267-70.

21.

Eprosartan does not affect the pharmacodynamics of warfarin.

Kazierad DJ, Martin DE, Ilson B, Boike S, Zariffa N, Forrest A, Jorkasky DK.

J Clin Pharmacol. 1998 Jul;38(7):649-53.

PMID:
9702851
22.

Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure.

Piltz JR, Stone RA, Boike S, Everitt DE, Shusterman NH, Audet P, Zariffa N, Jorkasky DK.

J Ocul Pharmacol Ther. 1998 Jun;14(3):203-16.

PMID:
9671428
23.

Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations.

Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK.

Clin Pharmacol Ther. 1998 Jun;63(6):617-22.

PMID:
9663175
24.
25.

Urine drug screening results from volunteers in phase I clinical pharmacology studies: are we being misled?

Ramey KL, Kovacs SJ, Martin DE, Jorkasky DK.

J Clin Pharmacol. 1998 May;38(5):413-6.

PMID:
9602952
26.

Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men.

Wilson DE, Meikle AW, Boike SC, Fairless AJ, Etheredge RC, Jorkasky DK.

J Clin Pharmacol. 1998 Jan;38(1):54-9.

PMID:
9597560
27.

A dose proportionality study of eprosartan in healthy male volunteers.

Chapelsky MC, Martin DE, Tenero DM, Ilson BE, Boike SC, Etheredge R, Jorkasky DK.

J Clin Pharmacol. 1998 Jan;38(1):34-9.

PMID:
9597557
28.
29.
30.

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.

Martin DE, Chapelsky MC, Ilson B, Tenero D, Boike SC, Zariffa N, Jorkasky DK.

J Clin Pharmacol. 1998 Feb;38(2):129-37.

PMID:
9549643
31.

SK&F107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies: a phase I trial.

Nemunaitis J, Martin DE, Willis DL, Freed MI, Levitt B, Richards DA, Cox JV, Kimmel GT, Hyman WJ, Jorkasky DK, Brocks DR.

Am J Clin Oncol. 1998 Apr;21(2):189-94. Erratum in: Am J Clin Oncol 1998 Dec;21(6):542.

PMID:
9537210
32.

Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.

Tenero DM, Martin DE, Ilson BE, Boyle DA, Boike SC, Carr AM, Lundberg DE, Jorkasky DK.

Ann Pharmacother. 1998 Mar;32(3):304-8.

PMID:
9533060
33.

Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.

Martin DE, Zussman BD, Everitt DE, Benincosa LJ, Etheredge RC, Jorkasky DK.

J Clin Psychopharmacol. 1997 Dec;17(6):451-9.

PMID:
9408807
34.

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.

Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R, Jorkasky DK.

Clin Pharmacol Ther. 1997 Oct;62(4):417-25.

PMID:
9357393
35.

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.

Martin DE, Tompson D, Boike SC, Tenero D, Ilson B, Citerone D, Jorkasky DK.

Br J Clin Pharmacol. 1997 Jun;43(6):661-4.

36.

Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults.

Boike SC, Ilson B, Zariffa N, Jorkasky DK.

Am J Health Syst Pharm. 1997 May 15;54(10):1172-6.

PMID:
9161624
37.

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.

Martin DE, DeCherney GS, Ilson BE, Jones BA, Boike SC, Freed MI, Jorkasky DK.

J Clin Pharmacol. 1997 Feb;37(2):155-9.

PMID:
9055142
38.

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.

Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK.

J Infect Dis. 1996 Sep;174(3):463-9.

PMID:
8769601
39.

Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose.

Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, Jorkasky DK.

J Clin Pharmacol. 1996 Aug;36(8):732-9.

PMID:
8877678
40.

Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients.

Brocks DR, Freed MI, Martin DE, Sellers TS, Mehdi N, Citerone DR, Boppana V, Levitt B, Davies BE, Nemunaitis J, Jorkasky DK.

Pharm Res. 1996 May;13(5):794-7.

PMID:
8860439
41.

Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.

Benincosa LJ, Audet PR, Lundberg D, Zariffa N, Jorkasky DK.

Biopharm Drug Dispos. 1996 Apr;17(3):249-58.

PMID:
8983399
42.

Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species.

Ruggieri EV, Bugelski PJ, Kaplan JM, Everitt D, Lipani J, Jorkasky DK, Boike SC, DeClement F, Moore FD Jr, Herzyk DJ.

J Clin Immunol. 1996 Mar;16(2):97-106.

PMID:
8690778
43.

Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.

Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, Jorkasky DK.

J Clin Pharmacol. 1994 Dec;34(12):1199-207.

PMID:
7738216
44.

Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers.

Freed MI, Audet PR, Zariffa N, Krishna GG, Ilson BE, Everitt DE, Brown LE, Rizzo SM, Nichols AI, Jorkasky DK.

J Clin Pharmacol. 1994 Nov;34(11):1098-108.

PMID:
7876402
45.
46.

Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.

Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK.

Clin Pharmacol Ther. 1994 Apr;55(4):418-26.

PMID:
8162668
47.

Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients.

Jorkasky DK, Audet P, Shusterman N, Ilson B, Dafoe D, Hedrich D, Stote RM.

Am J Kidney Dis. 1992 Jun;19(6):567-72.

PMID:
1350709
48.

Intraoperative versus routine hemodialysis in end-stage renal disease patients undergoing open-heart surgery.

Ilson BE, Bland PS, Jorkasky DK, Shusterman N, Allison NL, Dubb JW, Parr GV, Goebel TK, Stote RM.

Nephron. 1992;61(2):170-5.

PMID:
1630541
49.

Metabolic acidosis in a diabetic man.

Ilson BE, Bland PS, Allison NL, Jorkasky DK, Stote RM.

Hosp Pract (Off Ed). 1990 Oct 15;25(10):132-5, 138. No abstract available.

PMID:
2120250
50.

Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects.

Ilson BE, Jorkasky DK, Curnow RT, Stote RM.

J Clin Endocrinol Metab. 1989 Jul;69(1):212-4.

PMID:
2543692

Supplemental Content

Loading ...
Support Center